BioMarin Pharma (BMRN) Trades Higher After Pfizer (PFE) Wins Medivation (MDVN) (SNY)

August 22, 2016 7:15 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BioMarin Pharma (NASDAQ: BMRN) traded higher pre-market on Monday after Pfizer (NYSE: PFE) and Medivation (Nasdaq: MDVN) announced that they entered into a merger agreement.

Gains may be tied to speculation that Sanofi (NYSE: SNY), which had also been interested in Medivation, sees BioMarin as an alternative. The rumor was reported by Betaville in June.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Rumors, Trader Talk

Related Entities

Definitive Agreement

Add Your Comment